Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) Equity Average (2025)

RedHill Biopharma has reported Equity Average over the past 2 years, most recently at -$72000.0 for Q4 2025.

  • Quarterly Equity Average changed N/A to -$72000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$72000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$207500.0 for FY2025, 84.12% up from the prior year.
  • Equity Average was -$72000.0 for Q4 2025 at RedHill Biopharma, up from -$4.5 million in the prior quarter.
  • Over five years, Equity Average peaked at -$72000.0 in Q4 2025 and troughed at -$4.5 million in Q2 2025.